Perspective Therapeutics, Inc. (NYSE:CATX) Shares Sold by Altium Capital Management LLC

Altium Capital Management LLC decreased its position in shares of Perspective Therapeutics, Inc. (NYSE:CATX) by 68.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 92,224 shares of the company’s stock after selling 197,776 shares during the period. Altium Capital Management LLC owned about 0.14% of Perspective Therapeutics worth $294,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. State Street Corp increased its holdings in Perspective Therapeutics by 119.6% during the 3rd quarter. State Street Corp now owns 2,190,239 shares of the company’s stock worth $29,240,000 after purchasing an additional 1,192,812 shares during the period. Affinity Asset Advisors LLC raised its holdings in Perspective Therapeutics by 160.0% in the fourth quarter. Affinity Asset Advisors LLC now owns 1,300,000 shares of the company’s stock valued at $4,147,000 after acquiring an additional 800,000 shares in the last quarter. Walleye Capital LLC lifted its stake in Perspective Therapeutics by 2,526.2% in the fourth quarter. Walleye Capital LLC now owns 475,792 shares of the company’s stock worth $1,518,000 after acquiring an additional 457,675 shares during the last quarter. Jump Financial LLC acquired a new position in Perspective Therapeutics during the 4th quarter worth approximately $688,000. Finally, Geode Capital Management LLC increased its position in shares of Perspective Therapeutics by 12.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,164,204 shares of the company’s stock valued at $15,546,000 after purchasing an additional 129,654 shares during the last quarter. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

Perspective Therapeutics Stock Performance

Shares of CATX stock opened at $1.94 on Friday. The stock’s 50-day moving average price is $2.41 and its 200 day moving average price is $5.18. Perspective Therapeutics, Inc. has a 52-week low of $1.60 and a 52-week high of $19.05.

Insider Transactions at Perspective Therapeutics

In other Perspective Therapeutics news, CEO Johan M. Spoor acquired 22,026 shares of the stock in a transaction on Friday, March 28th. The shares were bought at an average price of $2.24 per share, with a total value of $49,338.24. Following the acquisition, the chief executive officer now owns 59,383 shares of the company’s stock, valued at $133,017.92. This trade represents a 58.96 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Robert F. Williamson III bought 22,192 shares of the business’s stock in a transaction dated Friday, March 28th. The shares were acquired at an average cost of $2.27 per share, with a total value of $50,375.84. Following the completion of the purchase, the director now owns 70,837 shares in the company, valued at approximately $160,799.99. This represents a 45.62 % increase in their position. The disclosure for this purchase can be found here. Insiders purchased 115,696 shares of company stock worth $256,344 over the last 90 days. 3.52% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of brokerages recently commented on CATX. Lifesci Capital upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Thursday, March 6th. Wedbush reissued an “outperform” rating and set a $11.00 target price on shares of Perspective Therapeutics in a research report on Wednesday, March 26th. Truist Financial lowered their price target on Perspective Therapeutics from $21.00 to $10.00 and set a “buy” rating for the company in a report on Monday, April 7th. Royal Bank of Canada cut their price objective on shares of Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating on the stock in a report on Thursday, March 27th. Finally, Brookline Capital Management raised shares of Perspective Therapeutics to a “strong-buy” rating in a research report on Monday, March 10th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $12.75.

Perspective Therapeutics Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.